|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2001-4-12
|
|
pubmed:abstractText |
Twenty-six children with B-cell acute lymphoblastic leukaemia (B-ALL) or Murphy Stage III or IV B-cell non-Hodgkin's lymphoma (B-NHL) progressed or relapsed after first-line therapy with a short, intensive multiagent chemotherapy regimen [United Kingdom Childhood Cancer Study Group (UKCCSG) 9003] (n = 62) or a slightly less intensive regimen (UKCCSG 9002) (n = 112). Eight patients (4.6%) never achieved complete remission (CR) and 18 (10.3%) relapsed. Second-line therapy resulted in remission for eight patients (30%). All patients initially treated with the 9003 protocol died. Three patients (11.5%) in the 9002 group, including one who never achieved CR in the primary site, are alive after second-line therapy. This study confirms that the prognosis of relapsed or refractory B-ALL/B-NHL is poor and exceptionally so if relapse occurred less than 6 months from diagnosis. High-dose therapy with stem cell rescue was used in only seven patients; its role needs to be studied further.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0007-1048
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
112
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
965-8
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11298592-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11298592-Bone Marrow Transplantation,
pubmed-meshheading:11298592-Burkitt Lymphoma,
pubmed-meshheading:11298592-Child,
pubmed-meshheading:11298592-Combined Modality Therapy,
pubmed-meshheading:11298592-Cyclophosphamide,
pubmed-meshheading:11298592-Cytarabine,
pubmed-meshheading:11298592-Doxorubicin,
pubmed-meshheading:11298592-Etoposide,
pubmed-meshheading:11298592-Follow-Up Studies,
pubmed-meshheading:11298592-Humans,
pubmed-meshheading:11298592-Lymphoma, B-Cell,
pubmed-meshheading:11298592-Palliative Care,
pubmed-meshheading:11298592-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:11298592-Prednisone,
pubmed-meshheading:11298592-Recurrence,
pubmed-meshheading:11298592-Treatment Outcome,
pubmed-meshheading:11298592-Vincristine
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin's lymphoma treated with the UKCCSG 9003/9002 protocols.
|
|
pubmed:affiliation |
Department of Paediatric Oncology, The Royal Marsden Hospital NHS Trust/Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK. ayad.atra@rmh.thames.nhs.uk
|
|
pubmed:publicationType |
Journal Article
|
